Table 3.
Summary of pentacoordinated copper(II) complexes with ancillary ligands and better IC50 values (μM) in different cell lines.
| Compound | Metal geometry | Exposure time [h] | Cell lines | IC50 value [μM] | Main feature | Ref. | 
|---|---|---|---|---|---|---|
| Cu‐24 | Square pyramidal | 72 | A‐549 HCT‐116 HeLa MDA‐MB‐231 SH‐SY5Y HASM‐C1 HASM‐C2 | 1.93±1.56 1.79±0.43 3.13±0.51 3.60±0.37 1.08±0.63 >12.50 >12.50 | The anticancer activity depends on the presence of the amino group in the phen co‐ligand | [67] | 
| Cu‐32 | 48 | HUVEC C33A HeLa | 3.60±0.05, 2.22±0.17 1.02±0.03 | Anticancer activity depends on the phen co‐ligand and its aromaticity | [70] | |
| Cu‐37 | HeLa MCF‐7 Hep‐G2 | 0.46±0.01 0.94±0.06 0.47±0.06 | Anticancer activity depends on the presence of the phen ancillary ligand | [72] | ||
| Cu‐66 | 72 | A‐2780 MCF‐7 | 0.75±0.2 2.5±0.6 | Anticancer activity depends on the presence of the phen ancillary ligand | [88] | |
| Cu‐67 | A‐2780 MCF‐7 | 0.54±0.2 2.7±0.8 | ||||
| Cu‐68 | A‐2780 MCF‐7 HL‐60 HeLa | 0.29±0.01 3.5±1.2 1.51±0.37 4.2±0.6 |